Bioverativ Therapeutics Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.7M
Doctors Paid
419
Transactions
5,426
2021 Total
$3.7M
Payment Breakdown by Category
Royalty/License$11.8M (49.8%)
Research$9.4M (39.6%)
Consulting$763,459 (3.2%)
Travel$206,795 (0.9%)
Food & Beverage$61,800 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $11.8M | 8 | 49.8% |
| Unspecified | $9.4M | 3,133 | 39.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 370 | 6.0% |
| Consulting Fee | $763,459 | 229 | 3.2% |
| Travel and Lodging | $206,795 | 628 | 0.9% |
| Food and Beverage | $61,800 | 969 | 0.3% |
| Grant | $59,706 | 6 | 0.3% |
| Education | $1,692 | 83 | 0.0% |
Payments by Type
General
$14.3M
2,293 transactions
Research
$9.4M
3,133 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease | $1.6M | 0 | 195 |
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | $445,555 | 7 | 289 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | $421,428 | 8 | 56 |
| A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients >=12 Years of Age With Severe Hemophilia A | $416,341 | 0 | 44 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) | $384,223 | 3 | 16 |
| Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B | $344,430 | 4 | 293 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | $322,084 | 10 | 296 |
| A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease (PRECIZN-1) | $265,542 | 0 | 69 |
| A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) | $259,849 | 0 | 15 |
| Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | $257,230 | 1 | 46 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion | $243,667 | 0 | 26 |
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein Known as rFVIIIFc in Untreated Males With Severe Hemophilia A | $242,861 | 0 | 259 |
| An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A | $237,852 | 0 | 114 |
| A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A | $237,251 | 0 | 18 |
| Implications of Fc receptor-targeting in the down-regulation of inflammatory and angiogenic responses after hemarthrosis that contribute to the development of hemophilic arthropathy | $224,346 | 0 | 2 |
| A PHASE 1 SAFETY, TOLERABILITY, AND PHARMACOKINETICS & PHARMACODYNAMICS STUDY OF MULTIPLE-DOSE BIVV009 IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) | $214,915 | 0 | 8 |
| Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment | $203,662 | 9 | 101 |
| ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX | $191,998 | 0 | 58 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfu | $173,897 | 9 | 25 |
| Natural History Study of Factor IX Treatment and Complications B-Natural | $170,698 | 0 | 183 |
| A Prospective Study in Subjects With Severe Hemophilia A Who are Currently Receiving a Marketed FVIII Therapy | $137,855 | 0 | 40 |
| Study to promote fetal globin gene expression by gene editing of the - globin locus for the treatment of -hemoglobinopathies | $133,000 | 0 | 4 |
| A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment | $119,257 | 7 | 104 |
| A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease | $118,163 | 0 | 18 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza) | $112,747 | 0 | 11 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal | $112,455 | 0 | 31 |
| TITLE: TREATMENT PATTERNS, PATIENT OUTCOMES, AND HEALTHCARE CHARGES IN HEMOPHILIA AT HEMOPHILIA TREATMENT CENTERS IN THE INTERMOUNTAIN WEST | $110,936 | 0 | 2 |
| An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | $108,181 | 0 | 32 |
| Prevalence and etiology of subclinical joint bleeding and joint microbleeding in adults with hemophilic arthropathy | $100,000 | 0 | 1 |
| A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN | $96,435 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Catherine Broome, Md, MD | Hematology & Oncology | Washington, DC | $176,942 | $0 |
| Dr. Roshni Kulkarni, M.d, M.D | Pediatric Hematology-Oncology | Lansing, MI | $146,738 | $0 |
| Doris Quon, M.d, M.D | Hematology | Los Angeles, CA | $139,780 | $0 |
| Dr. Guillermo De Angulo, Md, MD | Pediatric Hematology-Oncology | Miami, FL | $139,200 | $0 |
| Michael Guerrera, Md, MD | Pediatrics | Washington, DC | $113,053 | $0 |
| Sandeep Rajan, M.d, M.D | Internal Medicine | Nashville, TN | $106,872 | $0 |
| Barbara Konkle, Md, MD | Hematology & Oncology | Seattle, WA | $102,479 | $0 |
| Dr. Amy Shapiro, Md, MD | Pediatric Hematology-Oncology | Indianapolis, IN | $100,126 | $0 |
| Dr. Guy Young, M.d, M.D | Pediatric Hematology-Oncology | Bozeman, MT | $76,610 | $0 |
| Vinod Balasa, M.d, M.D | Pediatric Hematology-Oncology | Madera, CA | $72,813 | $0 |
| Robert Sidonio, Md, MD | Pediatric Hematology-Oncology | Atlanta, GA | $72,373 | $0 |
| Dr. Margaret Ragni, Md, MD | Specialist | Pittsburgh, PA | $71,484 | $0 |
| Shannon Meeks, Md, MD | Pediatric Hematology-Oncology | Atlanta, GA | $71,246 | $0 |
| Dr. Lynn Malec, Md, MD | Hematology & Oncology | Milwaukee, WI | $69,384 | $0 |
| Dr. Joanna Davis, Md, MD | Pediatric Hematology-Oncology | Miami, FL | $67,093 | $0 |
| Dr. David Kuter, Md Dphil, MD DPHIL | Internal Medicine | Boston, MA | $61,485 | $0 |
| Adam Giermasz, M.d., Phd, M.D., PHD | Hematology & Oncology | Sacramento, CA | $59,407 | $0 |
| Dr. Joanna Davis, M.d, M.D | Pediatrics | Miami, FL | $56,084 | $0 |
| Michael Wang, Md, MD | Pediatric Hematology-Oncology | Aurora, CO | $49,985 | $0 |
| Dr. Melissa Singer, M.d., M.p.h, M.D., M.P.H | Pediatric Hematology-Oncology | Loxahatchee, FL | $49,420 | $0 |
| Mark Reding, Md, MD | Internal Medicine | Minneapolis, MN | $44,694 | $0 |
| Shawn Jobe, M.d, M.D | Pediatric Hematology-Oncology | Lansing, MI | $44,621 | $0 |
| Irina Murakhovskaya, M.d, M.D | Internal Medicine | Woodbury, NY | $40,211 | $0 |
| Eliot Williams, Md Phd, MD PHD | Hematology | Madison, WI | $38,147 | $0 |
| Joseph Kiss | Specialist | Pittsburgh, PA | $37,574 | $0 |
Ad
Top Products
- ALPROLIX $12.5M
- ELOCTATE $2.0M
Associated Products (8)
Payment Categories
- Food & Beverage $61,800
- Consulting $763,459
- Travel & Lodging $206,795
- Research $9.4M
- Royalties $11.8M
About Bioverativ Therapeutics Inc.
Bioverativ Therapeutics Inc. has made $23.7M in payments to 419 healthcare providers, recorded across 5,426 transactions in the CMS Open Payments database. In 2021, the company paid $3.7M. The top product by payment volume is ALPROLIX ($12.5M).
Payments were distributed across 44 medical specialties. The top specialty by payment amount is Pediatric Hematology-Oncology ($1.1M to 105 doctors).
Payment categories include: Food & Beverage ($61,800), Consulting ($763,459), Research ($9.4M), Travel & Lodging ($206,795), Royalties ($11.8M).
Bioverativ Therapeutics Inc. is associated with 8 products in the CMS Open Payments database, including ALPROLIX, ELOCTATE, and Eloctate.